These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35463750)

  • 1. Lack of Usefulness of Donor-Derived Cell-Free DNA as a Biomarker for Cardiac Allograft Vasculopathy: A Prospective Study.
    Jiménez-Blanco Bravo M; Pérez-Gómez L; Hernández-Pérez FJ; Arellano-Serrano C; Torres-Sanabria M; Gómez-Bueno M; Oteo-Domínguez JF; Mingo-Santos S; Segovia-Cubero J
    Front Cardiovasc Med; 2022; 9():856600. PubMed ID: 35463750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor-derived cell-free DNA is associated with cardiac allograft vasculopathy.
    Holzhauser L; Clerkin KJ; Fujino T; Alenghat FJ; Raikhelkar J; Kim G; Sayer G; Uriel N
    Clin Transplant; 2021 Mar; 35(3):e14206. PubMed ID: 33368611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of Association Between Donor-Derived Cell-Free DNA and Cardiac Allograft Vasculopathy.
    Alharethi R; Knight S; Luikart HI; Wolf-Doty T; Bride DL; Kim DT; Khush KK
    Clin Transplant; 2024 Jul; 38(7):e15416. PubMed ID: 39058520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Late gadolinium enhancement assessed by cardiac magnetic resonance imaging in heart transplant recipients with different stages of cardiac allograft vasculopathy.
    Braggion-Santos MF; Lossnitzer D; Buss S; Lehrke S; Doesch A; Giannitsis E; Korosoglou G; Katus HA; Steen H
    Eur Heart J Cardiovasc Imaging; 2014 Oct; 15(10):1125-32. PubMed ID: 24908664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients.
    Kueng N; Arcioni S; Sandberg F; Kuhn C; Banz V; Largiadèr CR; Sidler D; Amstutz U
    Front Genet; 2023; 14():1089830. PubMed ID: 36777723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Validation of a Plasma Donor-derived Cell-free DNA Assay to Detect Allograft Rejection and Injury in Lung Transplant.
    Rosenheck JP; Ross DJ; Botros M; Wong A; Sternberg J; Chen YA; Liang N; Baer A; Ahmed E; Swenerton R; Zimmermann BG; Fehringer G; Demko ZP; Olymbios M; Billings PR; Keller BC
    Transplant Direct; 2022 Apr; 8(4):e1317. PubMed ID: 35372675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of dd-cfDNA Levels in Clinically Stable Lung Allograft Recipients Beyond the Initial 2 y Posttransplant.
    Trindade AJ; Chapin KC; Mullican A; Gray JN; Hoy H; Demarest CT; Lambright ES; McPherson KA; Norfolk SG; Robbins IM; Bacchetta M; Erasmus DB; Shaver CM
    Transplant Direct; 2022 Dec; 8(12):e1411. PubMed ID: 36406896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of longitudinal myocardial deformation by 2-dimensional speckle-tracking echocardiography in heart transplant recipients: relation to coronary allograft vasculopathy.
    Clemmensen TS; Løgstrup BB; Eiskjær H; Poulsen SH
    J Heart Lung Transplant; 2015 Feb; 34(2):195-203. PubMed ID: 25108908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologist interrater reliability and clinical implications of elevated donor-derived cell-free DNA beyond heart transplant rejection, on behalf of the GRAfT investigators.
    Mehta A; Goldberg J; Bagchi P; Marboe C; Shah KB; Najjar SS; Hsu S; Rodrigo ME; Jang MK; Cochrane A; Tchoukina IF; Kong H; Lohmar BJ; Mcnair E; Valantine HA; Agbor-Enoh S; Berry GJ; Shah P
    J Heart Lung Transplant; 2024 Oct; ():. PubMed ID: 39424014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-Derived Cell-Free DNA for Kidney Allograft Surveillance after Conversion to Belatacept: Prospective Pilot Study.
    Osmanodja B; Akifova A; Oellerich M; Beck J; Bornemann-Kolatzki K; Schütz E; Budde K
    J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care.
    Keller M; Sun J; Mutebi C; Shah P; Levine D; Aryal S; Iacono A; Timofte I; Mathew J; Varghese A; Giner C; Agbor-Enoh S
    J Heart Lung Transplant; 2022 Apr; 41(4):458-466. PubMed ID: 35063338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of plasma donor-derived cell free DNA for lung allograft rejection diagnosis in lung transplant recipients.
    Ju C; Xu X; Zhang J; Chen A; Lian Q; Liu F; Liu H; Cai Y; Zou Y; Yang Y; Zhou Y; He J
    BMC Pulm Med; 2023 Jan; 23(1):37. PubMed ID: 36703125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition of Renal Patients Using AlloSure Into Community Kidney Care (TRACK): Protocol for Long-Term Allograft Surveillance in Renal Transplant Recipients.
    Dale BL; Bose S; Kuo S; Burns A; Daou P; Short J; Miles J
    JMIR Res Protoc; 2021 Mar; 10(3):e25941. PubMed ID: 33720033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study.
    Bu L; Gupta G; Pai A; Anand S; Stites E; Moinuddin I; Bowers V; Jain P; Axelrod DA; Weir MR; Wolf-Doty TK; Zeng J; Tian W; Qu K; Woodward R; Dholakia S; De Golovine A; Bromberg JS; Murad H; Alhamad T
    Kidney Int; 2022 Apr; 101(4):793-803. PubMed ID: 34953773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of donor-derived cell-free DNA between single versus double lung transplant recipients.
    Keller MB; Meda R; Fu S; Yu K; Jang MK; Charya A; Berry GJ; Marboe CC; Kong H; Luikart H; Ponor IL; Shah PD; Khush KK; Nathan SD; Agbor-Enoh S
    Am J Transplant; 2022 Oct; 22(10):2451-2457. PubMed ID: 35322546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor-derived Cell-free DNA Complements De Novo Class II DSA in Detecting Late Alloimmune Injury Post Kidney Transplantation.
    Butiu M; Obrisca B; Sibulesky L; Bakthavatsalam R; Smith KD; Gimferrer I; Warner P; Ismail G; Leca N
    Transplant Direct; 2022 Feb; 8(2):e1285. PubMed ID: 35187211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological Variation of Donor-Derived Cell-Free DNA in Stable Lung Transplant Recipients.
    Keller M; Mutebi C; Shah P; Levine D; Aryal S; Iacono A; Timofte I; Mathew J; Varghese A; Giner C; Agbor-Enoh S
    J Appl Lab Med; 2022 Jun; 7(4):901-909. PubMed ID: 35024828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac allograft vasculopathy in Dutch heart transplant recipients.
    Galli G; Caliskan K; Balk AH; van Domburg R; Birim O; Salerno-Uriarte J; Manintveld OC; Constantinescu AA
    Neth Heart J; 2016 Dec; 24(12):748-757. PubMed ID: 27586194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance for cardiac allograft vasculopathy: Practice variations among 50 pediatric heart transplant centers.
    Nandi D; Chin C; Schumacher KR; Fenton M; Singh RK; Lin KY; Conway J; Cantor RS; Koehl DA; Lamour JM; Kirklin JK; Pahl E
    J Heart Lung Transplant; 2020 Nov; 39(11):1260-1269. PubMed ID: 32861553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European Association of Cardiovascular Imaging/Cardiovascular Imaging Department of the Brazilian Society of Cardiology recommendations for the use of cardiac imaging to assess and follow patients after heart transplantation.
    Badano LP; Miglioranza MH; Edvardsen T; Colafranceschi AS; Muraru D; Bacal F; Nieman K; Zoppellaro G; Marcondes Braga FG; Binder T; Habib G; Lancellotti P;
    Eur Heart J Cardiovasc Imaging; 2015 Sep; 16(9):919-48. PubMed ID: 26139361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.